[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2044976T3 - Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion. - Google Patents

Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.

Info

Publication number
ES2044976T3
ES2044976T3 ES87890135T ES87890135T ES2044976T3 ES 2044976 T3 ES2044976 T3 ES 2044976T3 ES 87890135 T ES87890135 T ES 87890135T ES 87890135 T ES87890135 T ES 87890135T ES 2044976 T3 ES2044976 T3 ES 2044976T3
Authority
ES
Spain
Prior art keywords
procedure
flagelar
vaccines
preparations
aeruginous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87890135T
Other languages
English (en)
Inventor
Friedrich Prof Dr Dorner
Johann Dr Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2044976T3 publication Critical patent/ES2044976T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806Antigenic peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Vessels, Lead-In Wires, Accessory Apparatuses For Cathode-Ray Tubes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN PREPARACIONES ACTIVAS CONTRA LAS INFECCIONES PRODUCIDAS POR LA PSEUDOMONA AERUGINOSA, ES DECIR VACUNAS PARA LA INMUNIZACION ACTIVA Y PREPARACIONES DESTINADAS A LA PROTECCION PASIVA QUE CONTIENEN ANTICUERPOS, Y PROCEDIMIENTO PARA SU PREPARACION. LAS VACUNAS CONTIENEN ANTIGENO H FLAGELAR PROTECTOR DEL SEROTIPO-H A Y B, QUE CONSISTEN EN COMPONENTES MONOMEROS, ESTANDO CONSTITUIDO CADA UNO DE LOS COMPONENTES MONOMEROS POR AMINOACIDOS DETERMINADOS CON UNA SECUENCIA DE AMINOACIDOS N-TERMINAL Y PRESENTANDO UN PESO MOLECULAR DETERMINADO. LAS VACUNAS SE PREPARAN A PARTIR DE SOLUCIONES PURAS DE ANTIGENO H FLAGELAR. LAS PREPARACIONES QUE CONTIENEN INMUNOGLOBULINA G CONTIENEN ANTICUERPOS H FLAGELARES OBTENIDOS DEL PLASMA SANGUINEO DE DONANTES HUMANOS INMUNIZADOS O DE ANIMALES MAMIFEROS INMUNIZADOS. AQUELLAS PUEDEN PURIFICARSE POR UN PROCEDIMIENTO DE CROMATOGRAFIA DE AFINIDAD.
ES87890135T 1986-06-24 1987-06-15 Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion. Expired - Lifetime ES2044976T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT1716/86A AT391080B (de) 1986-06-24 1986-06-24 Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen

Publications (1)

Publication Number Publication Date
ES2044976T3 true ES2044976T3 (es) 1994-01-16

Family

ID=3519452

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87890135T Expired - Lifetime ES2044976T3 (es) 1986-06-24 1987-06-15 Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.

Country Status (9)

Country Link
US (1) US4946677A (es)
EP (1) EP0252064B1 (es)
JP (2) JPH0830011B2 (es)
AT (2) AT391080B (es)
CA (1) CA1306690C (es)
DE (1) DE3782771D1 (es)
DK (1) DK173123B1 (es)
ES (1) ES2044976T3 (es)
FI (1) FI86508C (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237053A (en) * 1986-06-24 1993-08-17 Immuno Aktiengesellschaft Preparation active against Pseudomonas aeruginosa infections and methods of producing them
AT390192B (de) * 1988-08-29 1990-03-26 Immuno Ag Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobuling-h|ltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen
AU5405794A (en) * 1992-10-16 1994-05-09 Brigham And Women's Hospital O-derivatized alginic acid antigens
GB9701489D0 (en) 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
US6749831B1 (en) * 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP1499712A4 (en) 2002-04-12 2008-04-16 Melbourne Health HEPATITIS B VIRUS VARIANTS WITH REDUCED SENSITIVITY TO NUCLEOSIDANALOGES AND USE THEREOF
JP2007530029A (ja) * 2004-03-26 2007-11-01 クアーク・ファーマスーティカルス、インコーポレイテッド アネキシンii及びその使用
EP1874923A4 (en) 2005-04-08 2010-08-04 Melbourne Health VARIANTS OF THE HEPATITIS B VIRUS WITH RESISTANCE TO ANTIVIRAL NUCLEOSIDAGENTS AND APPLICATIONS THEREOF
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US8263078B2 (en) 2007-09-05 2012-09-11 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
WO2011046504A1 (en) * 2009-10-18 2011-04-21 Glycorex Ab Method and product for blood treatment and purification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674863A (en) * 1969-12-08 1972-07-04 Parke Davis & Co Polyvalent immunizing agents and methods for their production
US3987164A (en) * 1970-10-20 1976-10-19 Yuzuru Homma Method for prevention of pseudomonas aeruginosa infections
US3928565A (en) * 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
FR2227861B1 (es) * 1973-05-04 1976-07-02 Anvar
US4075321A (en) * 1973-05-04 1978-02-21 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
JPS51133489A (en) * 1975-05-14 1976-11-19 Tokyo Daigaku Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities
US4298597A (en) * 1979-09-04 1981-11-03 University Of Saskatchewan Vaccine for diarrhea caused by E. coli
JPS60248625A (ja) * 1984-05-25 1985-12-09 Mitsui Toatsu Chem Inc 抗緑膿菌モノクロ−ナル抗体、その製法ならびに用途
AT384032B (de) * 1985-01-14 1987-09-25 Immuno Ag Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
US4693891A (en) * 1985-09-09 1987-09-15 Miles Laboratories, Inc. Vaccine for Pseudomonas aeruginosa
FR2597344B1 (fr) * 1986-04-16 1989-06-23 Merieux Inst Perfectionnement au procede de purification d'antigenes proteiques de bacteries appartenant au genre bordetella, en vue de l'obtention d'un vaccin acellulaire.

Also Published As

Publication number Publication date
ATA171686A (de) 1990-02-15
FI86508B (fi) 1992-05-29
EP0252064A3 (en) 1989-03-15
JP2534470B2 (ja) 1996-09-18
DK173123B1 (da) 2000-01-31
DK322287D0 (da) 1987-06-24
JPH0853367A (ja) 1996-02-27
CA1306690C (en) 1992-08-25
AT391080B (de) 1990-08-10
ATE82687T1 (de) 1992-12-15
FI872750A (fi) 1987-12-25
EP0252064B1 (de) 1992-11-25
FI86508C (fi) 1992-09-10
JPS635029A (ja) 1988-01-11
FI872750A0 (fi) 1987-06-22
US4946677A (en) 1990-08-07
EP0252064A2 (de) 1988-01-07
DK322287A (da) 1987-12-25
JPH0830011B2 (ja) 1996-03-27
DE3782771D1 (de) 1993-01-07

Similar Documents

Publication Publication Date Title
ES2044976T3 (es) Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.
ES2057191T5 (es) Metodo de produccion para una composicion que contiene proteinas.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
NO167924C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive thymopentinanaloger
ATE50260T1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ES2102347T3 (es) Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
ES2104535T1 (es) Vacuna que contiene proteina de membrana externa de bordetella pertussis, y metodo para elaborar tal vacuna.
ES2127294T3 (es) Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
ES2119165T3 (es) Nueva actividad de cofactor anticoagulante.
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
DK0412766T3 (da) Peptidfragmenter af HIV
Di Conza Protective action of passively transferred immune serum and immunoglobulin fractions against tissue invasive stages of the dwarf tapeworm, Hymenolepis nana
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DK56389D0 (da) Forhindring og behandling af retroviralt frembragte sygdomme
Warnock et al. Immunoglobulin classes of antibodies to Aspergillus fumigatus in patients with pulmonary aspergillosis
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
Eliakim et al. The Complement-fixation test in bilharziasis I. The value of different extracts of Schistosoma mansoni and Fasciola hepatica worms as antigens
EP0374053B1 (fr) Médicament pour le traitement ou la prévention par immunisation passive de l'infection par le virus HIV et procédés de préparation
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
ES2003842A4 (es) Procedimiento para la preparacion de inmunogeno de moluscos aislado, de reactivos para el diagnostico de las bilharziosis humanas, de vacunas contra la esquistosomiasis y de compuestos inmunizantes que contienen dicho inmunogeno.
Magee et al. Individual variability in antibody response of human volunteers to infection of the upper respiratory tract by coxsackie A-21 virus

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 252064

Country of ref document: ES